Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 813-819

  Ma, Margaret K ^a   Zamboni, William C ^a   Radomski, Kristine M ^a   Furman, Wayne L ^a   Santana, Victor M ^a   Houghton, Peter J ^a,b   Hanna, Suzan K ^a   Smith, Audrey K ^a   Stewart, Clinton F ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASMS, COMPLEX AND MIXED; NEOPLASMS, CONNECTIVE AND SOFT TISSUE; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEUTROPENIA; TIME FACTORS;

EID: 0034099228     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
2. Thompson, J., Zamboni, W. C., Cheshire, P. J., Richmond, L. B., Luo, X., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of oral administration of irinotecan against neuroblastoma xenografts. Anti-Cancer Drugs, 8: 313-322, 1997.
3. Thompson, J., Zamboni, W. C., Chesire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J. A., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-431, 1997.
4. Furman, W., Stewart, C. F., Poquette, C., Pratt, C. B., Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffman, P. C., Meyer, W. H., Pappo, A. S., Walter, A.W., and Houghton, P. J. The direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children. J. Clin. Oncol., 17: 1815-1824, 1999.
5. Dodds, H. M., Haaz, M. C., Riou, J. F., Robert, J., and Rivory, L. P. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J. Pharmacol. Exp. Ther., 286: 578-583, 1998.
6. Haaz, M. C., Riche, C., Rivory, L. P., and Robert, J. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes. Drug Metab. Dispos., 26: 769-774, 1998.
7. Haaz, M. C., Rivory, L. P., Riche, C., Vernillet, L., and Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res., 58: 468-472, 1998.
8. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M-C., Mathieu-Boue, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-carnptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
9. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., De Forni, M., Extra, J. M., Mahjoubi, M., Herait, P., Armand, J. P., Bugat, R., Clavel, M., and Marty, M. E. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase I trials. Ann. Oncol., 6: 141-151, 1995.
10. Lokiec, F., Canal, P., Gay, C., Chatelut, E., Armand, J., and Roche, H. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol., 36: 79-82, 1995.
11. Rothenberg, M. L., Eckardt, J. R., Burris, H. A., III, Nelson, J., Kuhn, J. G., Chen, S. F., Hilsenbeck, S. G., Clark, G. M., Fields, S. M., and Rodriguez, G. I. Irinotecan (CPT-11) as second-line therapy for patients with 5- FU-refractory colorectal cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 13: A578, 1994.
12. Rivory, L. P., and Robert, J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantification of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J. Chromatogr. Biol. Biomed. Appl., 661: 133-141, 1994.
13. D'Argenio, D. Z., and Schumitzky, A. ADAPT II User's Guide. Los Angeles: Biomedical Simulations Resource, 1990.
14. Rivory, L. P., Haaz, M. C., Canal, P., Lokiec, F., Armand, J-P., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin. Cancer Res., 3: 1261-1266, 1997.
15. Vassal, G., Deroussent, A., Doz, F., Frappaz, D., Pein, F., Mignard, L., Vernillet, L., and Gouyette, A. Clinical pharmacology of irinotecan (CPT-11) in children. Proc. Am. Soc. Clin. Oncol., 17: 187a, 1998.
16. Noe, D. A. Noncompartmental pharmacokinetic analysis. In: L. B. Grochow, and M. M. Ames (eds.), A Clinician's Guide to Chemotherapy: Pharmacokinetics and Pharmacodynamics, pp. 520-521. Baltimore, MD: Williams and Wilkins, 1998.
17. Zamboni, W. C., Crom, W. R., Houghton, P. J., Thompson, J. C., and Stewart, C. F. Plasma protein binding of SN-38: the active metabolite of irinotecan. Pharmacotherapy, 16: 500, 1996.
18. Abigerges, D., Chabot, G. G., Armand, J-P., Herait, P., Gouyette, A., and Gandia, D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every three weeks in cancer patients. J. Clin. Oncol., 13: 210-221, 1995.
19. Catimel, G., Chabot, G. G., Guastalla, J. P., Dumortier, A., Cote, C., Engel, C., Gouyette, A., Mathieu-Boue, A., Mahjoubi, M., and Clavel, M. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann. Oncol., 6: 133-140, 1995.
20. Rothenberg, M. L., Kuhn, J. G., Burris, H. A., Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., Rodriguez, G. I., Rock, M. K., and Von Hoff, D. D. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11: 2194-2204, 1993.
21. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S. D., Jones, R. J., Burke, P. J., Cheng, Y. C., Grochow, L. B., and Kaufmann, S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12: 2193-2203, 1994.
22. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., and Chen, T. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-1-(1-piperidino)-1-piperdino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
23. Burke, T. G., Zoorob, G., Slatter, J. G., and Schaaf, L. J. In vitro protein binding of CPT-11 metabolites SN-38, SN-38 glucuronide (SN-38G), and APC and possible displacement by commonly used comedications. Proc. Am. Soc. Clin. Oncol., 17: 195, 1998.
24. Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T-C., Sun, M., Pulliam, S., and Gonzalez, C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 709-715, 1996.
25. Herben, V. M. M., Schellens, J. H. M., Swart, M., Gruia, M., Vernillet, L., Beijnen, J. H., and ten Bokkel Huinink, W. W. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J. Clin. Oncol., 17: 1897-1905, 1999.
26. Petros, W. P., Schaaf, L. J., Cokgor, I., Kerby, T. A., Colvin, O. M., Friedman, A. H., Knuth, D. W., Elfring, G. L., and Friedman, H. S. Reduced systemic exposure to irinotecan and its active metabolite in patients with glioma receiving concurrent anticonvulsants and corticosteroids. Pharmacotherapy, 18: 1146, 1998.
27. Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., Cloughsey, T., Stewart, E. S., Colvin, O. M., Provenzale, J. M., McLendon, R. E., Bigner, D. D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., MaIczyn, J., Elfring, G. L., and Miller, L. L. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol., 17: 1516-1525, 1999.
28. Sasaki, Y., Hakusui, Y., Mizuno, S., Morita, M., Miya, T., and Eguchi, K. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite, SN-38. Jpn. J. Cancer Res., 36: 101-110, 1995.
29. Saliba, F., Hagipantelli, R., Misset, J-L., Bastian, G., Vassal, G., Bonnay, M., Herait, P., Cote, C., Mahjoubi, M., Mignard, D., and Cvitkovic, E. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J. Clin. Oncol., 16: 2745-2751, 1998.
30. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
31. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.